Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	LCZ696 200 mg	479
Overall Study	STARTED	LCZ696 400 mg	473
Overall Study	STARTED	Olmesartan 20 mg	486
Overall Study	Full Analysis Set (FAS)	LCZ696 200 mg	479
Overall Study	Full Analysis Set (FAS)	LCZ696 400 mg	472
Overall Study	Full Analysis Set (FAS)	Olmesartan 20 mg	484
Overall Study	Safety Set (SAF)	LCZ696 200 mg	478
Overall Study	Safety Set (SAF)	LCZ696 400 mg	472
Overall Study	Safety Set (SAF)	Olmesartan 20 mg	484
Overall Study	COMPLETED	LCZ696 200 mg	455
Overall Study	COMPLETED	LCZ696 400 mg	454
Overall Study	COMPLETED	Olmesartan 20 mg	464
Overall Study	NOT COMPLETED	LCZ696 200 mg	24
Overall Study	NOT COMPLETED	LCZ696 400 mg	19
Overall Study	NOT COMPLETED	Olmesartan 20 mg	22

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01785472/flow